Ophthalmology Times
Discover key glaucoma breakthroughs from AAO 2025, including drop-free IOP control, safer laser surgery, and personalized cataract lens choices.
At the 2025 American Academy of Ophthalmology meeting, glaucoma experts shared exciting advancements pointing toward a future with safer procedures, more predictable pressure control, and increasingly personalized treatment options. Presentations from Dr. Inder Paul Singh, Dr. Sahar Bedrood, and Dr. John Berdahl highlighted how innovations in drug delivery, surgical visualization, and cataract planning are reshaping patient care.*
Presented by: Dr. Inder Paul Singh
Dr. Singh’s talk focused on the iDose implant, a tiny device that releases a prostaglandin medication from inside the eye during cataract surgery, helping many patients reduce or eliminate daily glaucoma drops.
Dr. Singh emphasized that the safety profile has been excellent. He reported no significant swelling or inflammation, and no extra postoperative steroids were needed.
For many patients, the iDose implant may offer:
Because the implant is placed during cataract surgery and doesn’t require advanced angle surgery skills, Dr. Singh believes more surgeons will be able to offer it in the future.
Presented by: Dr. Sahar Bedrood
Dr. Bedrood showcased a major leap in visualization technology for endoscopic cyclophotocoagulation (ECP), a laser treatment that targets the ciliary body to help lower eye pressure.
Her reaction to the new Leos endoscopic laser system was simple: “I’ve never seen the ciliary body so clearly.”
The Leos system provides:
This level of detail let Dr. Bedrood use lower energy while maintaining strong pressure-lowering results, potentially reducing inflammation and improving comfort.
OR staff praised the device’s straightforward design (“one button, one click”), which made it easier to use than older endoscopes.
Better visualization means:
For patients needing ECP, this could translate to a safer, more predictable pressure-lowering experience.
Presented by: Dr. John Berdahl
Dr. Berdahl focused on patients who have both glaucoma and pseudoexfoliation (PXF), a condition that weakens the eye’s internal support system. These patients often need cataract surgery, but lens selection can be more complicated.
Multifocal and extended-depth-of-focus lenses can work for mild glaucoma but may not be ideal for moderate disease, where contrast loss is more pronounced. Toric lenses, however, remain safe and effective.
For PXF patients, lens decisions aren’t one-size-fits-all. Dr. Berdahl reinforced that individualized planning is essential for maintaining good long-term vision.
The Big Picture: Where Glaucoma Care Is Heading
Across these presentations, three major themes emerged:
Sustained-release implants like iDose are making long-term pressure control easier and more reliable.
New visualization tools are helping surgeons perform safer, more targeted procedures.
From laser therapy to cataract lens selection, treatment is becoming more tailored to each patient’s anatomy, diagnosis, and long-term visual needs.
Together, these innovations point to a future where glaucoma care is more predictable, more personalized, and more patient-friendly than ever before.
* Ophthalmology Times (November 26, 2025). “AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision” ophthalmologytimes.com
To ensure that we always provide you with high-quality, reliable information, The Glaucoma Community closely vets all sources. We do not, however, endorse or recommend any specific providers, treatments, or products, and the use of a given source does not imply an endorsement of any provider, treatment, medication, procedure, or device discussed within.
Source: {{articlecontent.article.sourceName}}
Receive daily updated expert-reviewed article summaries. Everything you need to know from discoveries, treatments, and living tips!
Already a Responsum member?
Available for Apple iOS and Android
Add Comments
Cancel